EGFR and non-small cell lung carcinoma: As the link between EGFR mutations in NSCLC and response to EGFR tyrosine kinase inhibitor (EGFR TKI) therapy was further elucidated [7], the clinical utility of ctDNA was more robustly investigated via preplanned analyses in large-scale studies.